Enrollment Completed in STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma
“This milestone marks a significant step forward in our commitment to bringing more advanced therapies to patients. We extend our gratitude to the participants, investigators, and clinical teams whose dedication and collaboration have made this achievement possible significantly ahead of our original timelines,” stated Pedro Lichtinger, Chairman and CEO of Starton Therapeutics. “With enrollment now complete, we are poised to advance to the next stages of clinical development, furthering our mission to expand and replace lenalidomide in key segments of MM and bring to CLL patients a new mode of action with proven efficacy.”
Share:
More News
“KEYTRUDA has helped transform the treatment of certain cancers, and we continue to pursue innovations that build on this breakthrough medicine to give patients and those who treat them better experiences,” said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. “If approved,
“We are disappointed for ovarian cancer patients desperately lacking new treatment options. There has been a great deal of work across the industry in this immunologically cold tumor, yet there are still few treatment options that improve survival in this very difficult-to-treat tumor type. We are still on track to
“The improvement in survival seen in ROSELLA, without an increased safety burden, brings us closer to delivering a new standard-of-care treatment for patients with platinum-resistant ovarian cancer,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer. “We deeply appreciate the patients and investigators who participated in the trial, and we look
“We are grateful for the ongoing guidance and support from the FDA and are very pleased that the agency is fully aligned on our plans related to the Phase 3 trial,” said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. “The Phase 2 OVATION 2 study data are
